Paul Stoffels is continuing his transformation of Galapagos into a company with CAR-T and small molecule platforms and is aiming to seal more M&A deals before the end of this year.
Galapagos is continuing to evolve under the leadership of Paul Stoffels, with the Belgium-headquartered biotech building towards its goal of bringing a ‘point-of-care’ CAR-T therapy to patients worldwide.
Speaking to Scrip just ahead of its Q2 results, Stoffels said the company could eventually be well placed to meet unmet global demand for CAR-Ts, which currently can only
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
